S&P Futures
5,966.50 +8.25 (+0.14%) Dow Futures
43,981.00 +80.00 (+0.18%) Nasdaq Futures
20,939.25 +45.25 (+0.22%) Russell 2000 Futures
2,409.60 +3.80 (+0.16%) Crude Oil
71.61 -0.08 (-0.11%) Gold
2,668.50 -7.80 (-0.29%)
Unicycive Therapeutics, Inc. (UNCY)
After hours:
| Previous Close | 0.4948 |
| Open | 0.4979 |
| Bid | 0.4919 x 100 |
| Ask | 0.4957 x 100 |
| Day's Range | 0.4763 - 0.5020 |
| 52 Week Range | 0.2020 - 1.8180 |
| Volume | |
| Avg. Volume | 2,226,614 |
| Market Cap | 47.367M |
| Beta (5Y Monthly) | 2.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3600 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.25 |
GlobeNewswireUnicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
– Late-Breaker Poster Presentation Highlights Favorable Safety & Tolerability of OLC – – Two Publications Recently Issued Featuring OLC and UNI-494 – LOS ALTOS, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that multiple presentations were delivered at the American Society of Nephrology (ASN) Kidney Week 2024 that hi
- GlobeNewswire
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024
LOS ALTOS, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024 at 10:00 a.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website un
